Mineralocorticoid receptor agonists (MRAs), until recently, had not beenstudied in major cardiorenal outcome trials among individuals with DKD.Although there is some evidence of kidney benefit with the older MRAs likeeplerenone or spironolactone (reduction of albuminuria when combined with anACEi or ARB compared to ACEi or ARB alone), clinical practice guidelineshave not recommended these agents as part of the standard of care.21,40,41 Incontrast, the nsMRA finerenone has been included in the current KDIGO andAmerican Diabetes Association (ADA) guidelines.21,41. Here, NR3C2 is linked to diabetic kidney disease.